Comparison of melanoma antigen recognized by T cells (MART-1) to HMB-45: additional evidence to support a common lineage for angiomyolipoma, lymphangiomyomatosis, and clear cell sugar tumor.
Comparison of melanoma antigen recognized by T cells (MART-1) to HMB-45: additional evidence to support a common lineage for angiomyolipoma, lymphangiomyomatosis, and clear cell sugar tumor.
复制标题
T 细胞 (MART-1) 识别的黑色素瘤抗原与 HMB-45 的比较：支持血管平滑肌脂肪瘤、淋巴管肌瘤病和透明细胞糖瘤共同谱系的额外证据。
作者：
P. Fetsch;Fetsch Jf;F. Marincola;W. Travis;Batts Kp;A. Abati
T细胞识别的黑色素瘤抗原抗体(抗MART-1，克隆M2-7C10)是一种新发现的针对跨膜蛋白的抗体，以前仅在正常皮肤黑素细胞、视网膜组织和恶性黑色素瘤(MM)中检测到。这种抗体是国家卫生研究院/国家癌症研究所正在进行的免疫治疗方案的基础。HMB-45是一种针对黑素小体前糖蛋白的抗体，虽然主要用于MM的诊断，但在血管肌肉脂肪瘤(AML)、淋巴管肌瘤/淋巴管肌瘤病(LAM)和透明细胞糖瘤(CCST)中显示出一致的染色，这三种肿瘤是基于常见的血管周围上皮样细胞而被认为相关的，这些肿瘤表现出不同程度的平滑肌分化、黑素生成和胞浆内膜结合颗粒。为了比较抗MART-1和HMB-45的免疫反应模式，我们对已知表达HMB-45的非黑素细胞肿瘤(AML、LAM、CCST)进行了亲和素-生物素免疫过氧化物酶检测。石蜡包埋材料的抗Mart-1染色需要微波前处理。结果表明，10例AML均为抗MART-1和HMB-45阳性，4例LAM均为HMB-45阳性，其中1例抗MART-1阳性，4例CCST中3例表达HMB-45，1例抗MART-1阳性。我们的发现进一步支持了先前提出的AML、LAM和CCST之间的关系的研究。对于这些非黑素细胞肿瘤，抗MART-1和HMB-45具有相似的特异性，但前者似乎是这些病变的不太敏感的标志物。在类似情况下，抗MART-1和HMB-45是潜在有用的临床标记物。
The antibody to the melanoma antigen recognized by T cells (anti-MART-1, clone M2-7C10) is a newly described antibody to a transmembrane protein previously detected only in normal skin melanocytes, retinal tissue, and malignant melanoma (MM). This antibody is the basis for ongoing immunotherapy protocols at the National Institutes of Health/National Cancer Institute. HMB-45, an antibody directed against a premelanosome glycoprotein, although used predominantly for the diagnosis of MM, has shown consistent staining in angiomyolipoma (AML), lymphangiomyoma/lymphangiomyomatosis (LAM), and clear cell sugar tumor (CCST), a group of tumors proposed to be related on the basis of their common perivascular epithelioid cells, which exhibit various degrees of smooth muscle differentiation, melanogenesis, and intracytoplasmic membrane bound granules. To compare the immunoreactive patterns of anti-MART-1 with those of HMB-45, we performed avidin-biotin immunoperoxidase testing on nonmelanocytic neoplasms (AMLs, LAMs, CCSTs) known to express HMB-45. Microwave pretreatment was necessary for anti-MART-1 staining on paraffin-embedded material. Our results showed that all of the 10 cases of AML were immunoreactive for both anti-MART-1 and HMB-45; that all of the 4 cases of LAM were positive for HMB-45, with 1 of the 4 reacting with anti-MART-1; and that 3 of the 4 cases of CCST expressed HMB-45, whereas 1 of the 4 was positive for anti-MART-1. Our findings lent additional support to previous studies that proposed a relationship between AML, LAM, and CCST. Anti-MART-1 and HMB-45 share similar specificities for these nonmelanocytic tumors, but the former seems to be a less sensitive marker for these lesions. In similar circumstances, anti-MART-1 and HMB-45 are potentially useful clinical markers.